Cargando…
Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment
Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555549/ https://www.ncbi.nlm.nih.gov/pubmed/23359786 http://dx.doi.org/10.2147/IJGM.S38594 |
_version_ | 1782257046753640448 |
---|---|
author | Adelman, Daphne T Liebert, Karen JP Nachtigall, Lisa B Lamerson, Michele Bakker, Bert |
author_facet | Adelman, Daphne T Liebert, Karen JP Nachtigall, Lisa B Lamerson, Michele Bakker, Bert |
author_sort | Adelman, Daphne T |
collection | PubMed |
description | Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness among health care professionals, the insidious onset of differentiating features, and because patients are likely to present with complaints typical of other conditions more frequently seen in primary care. Early identification of acromegaly facilitates prompt treatment initiation and may minimize the permanent effects of excess growth hormone. The primary treatment for many patients will be pituitary surgery, although not all patients will be eligible for surgery or achieve a surgical cure. If biochemical control is not achieved following surgery, other treatment options include medical therapy and radiation therapy. Improved biochemical control may only alleviate rather than reverse the associated comorbidities. Thus, lifelong monitoring of patient health is needed, with particular attention to the management of cardiovascular risk factors. It is additionally important to consider the impact of both disease and treatment on patients’ quality of life and minimize that impact where possible, but particularly for chronic therapies. For the majority of patients, chronic therapy is likely to include somatostatin analog injections. In some circumstances, it may be possible to extend the dosing interval of the analog once good biochemical control is achieved. Additional convenience may be gained from the possibility of self-/partner administration of treatment or administration of treatment by a health care professional at home. Overall, it is clear that the care of patients with acromegaly requires a highly coordinated approach involving numerous specialties (eg, endocrinology, surgery, cardiology). Further, patients’ needs must be at the core of management and every effort must be made to improve health care experiences and minimize treatment burdens. |
format | Online Article Text |
id | pubmed-3555549 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35555492013-01-28 Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment Adelman, Daphne T Liebert, Karen JP Nachtigall, Lisa B Lamerson, Michele Bakker, Bert Int J Gen Med Original Research Acromegaly is a rare disease most often caused by the prolonged secretion of excess growth hormone from a pituitary adenoma. The disease is associated with multiple significant comorbidities and increased mortality. The delay to diagnosis is often long. This may be because of low disease awareness among health care professionals, the insidious onset of differentiating features, and because patients are likely to present with complaints typical of other conditions more frequently seen in primary care. Early identification of acromegaly facilitates prompt treatment initiation and may minimize the permanent effects of excess growth hormone. The primary treatment for many patients will be pituitary surgery, although not all patients will be eligible for surgery or achieve a surgical cure. If biochemical control is not achieved following surgery, other treatment options include medical therapy and radiation therapy. Improved biochemical control may only alleviate rather than reverse the associated comorbidities. Thus, lifelong monitoring of patient health is needed, with particular attention to the management of cardiovascular risk factors. It is additionally important to consider the impact of both disease and treatment on patients’ quality of life and minimize that impact where possible, but particularly for chronic therapies. For the majority of patients, chronic therapy is likely to include somatostatin analog injections. In some circumstances, it may be possible to extend the dosing interval of the analog once good biochemical control is achieved. Additional convenience may be gained from the possibility of self-/partner administration of treatment or administration of treatment by a health care professional at home. Overall, it is clear that the care of patients with acromegaly requires a highly coordinated approach involving numerous specialties (eg, endocrinology, surgery, cardiology). Further, patients’ needs must be at the core of management and every effort must be made to improve health care experiences and minimize treatment burdens. Dove Medical Press 2013-01-18 /pmc/articles/PMC3555549/ /pubmed/23359786 http://dx.doi.org/10.2147/IJGM.S38594 Text en © 2013 Adelman et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Adelman, Daphne T Liebert, Karen JP Nachtigall, Lisa B Lamerson, Michele Bakker, Bert Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title | Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title_full | Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title_fullStr | Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title_full_unstemmed | Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title_short | Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
title_sort | acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3555549/ https://www.ncbi.nlm.nih.gov/pubmed/23359786 http://dx.doi.org/10.2147/IJGM.S38594 |
work_keys_str_mv | AT adelmandaphnet acromegalythediseaseitsimpactonpatientsandmanagingtheburdenoflongtermtreatment AT liebertkarenjp acromegalythediseaseitsimpactonpatientsandmanagingtheburdenoflongtermtreatment AT nachtigalllisab acromegalythediseaseitsimpactonpatientsandmanagingtheburdenoflongtermtreatment AT lamersonmichele acromegalythediseaseitsimpactonpatientsandmanagingtheburdenoflongtermtreatment AT bakkerbert acromegalythediseaseitsimpactonpatientsandmanagingtheburdenoflongtermtreatment |